Dana Faratian

4.3k total citations
59 papers, 2.2k citations indexed

About

Dana Faratian is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Dana Faratian has authored 59 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 29 papers in Oncology and 18 papers in Cancer Research. Recurrent topics in Dana Faratian's work include HER2/EGFR in Cancer Research (19 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Estrogen and related hormone effects (9 papers). Dana Faratian is often cited by papers focused on HER2/EGFR in Cancer Research (19 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Estrogen and related hormone effects (9 papers). Dana Faratian collaborates with scholars based in United Kingdom, United States and Japan. Dana Faratian's co-authors include David J. Harrison, Simon P. Langdon, Peter Mullen, Jeremy Thomas, Andrew H. Sims, Charlene Kay, John M.S. Bartlett, Sarah J. Aitken, In Hwa Um and Alexey Goltsov and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Dana Faratian

57 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dana Faratian United Kingdom 27 1.0k 879 557 314 293 59 2.2k
Soonmyoung Paik United States 14 1.2k 1.2× 1.1k 1.2× 568 1.0× 135 0.4× 480 1.6× 28 2.5k
Kevin D. Courtney United States 22 1.6k 1.6× 682 0.8× 754 1.4× 865 2.8× 118 0.4× 68 2.9k
Hiroyuki Takahashi Japan 31 1.2k 1.2× 879 1.0× 555 1.0× 1.3k 4.0× 402 1.4× 148 3.3k
Li Fu China 32 1.5k 1.5× 917 1.0× 963 1.7× 210 0.7× 136 0.5× 119 2.8k
Philip Jonsson United States 27 1.4k 1.4× 773 0.9× 902 1.6× 462 1.5× 485 1.7× 41 2.8k
Nancy Kerkvliet United States 18 983 1.0× 1.4k 1.6× 862 1.5× 408 1.3× 154 0.5× 30 2.9k
Abdelbaset Buhmeida Saudi Arabia 27 802 0.8× 795 0.9× 523 0.9× 261 0.8× 185 0.6× 101 2.0k
Björn Erikstein Norway 24 859 0.9× 1.3k 1.5× 702 1.3× 483 1.5× 968 3.3× 47 2.7k
Naofumi Kagara Japan 21 673 0.7× 637 0.7× 739 1.3× 220 0.7× 102 0.3× 65 1.6k
Rachel E. Ellsworth United States 25 1.1k 1.1× 720 0.8× 836 1.5× 191 0.6× 452 1.5× 91 2.2k

Countries citing papers authored by Dana Faratian

Since Specialization
Citations

This map shows the geographic impact of Dana Faratian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana Faratian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana Faratian more than expected).

Fields of papers citing papers by Dana Faratian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana Faratian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana Faratian. The network helps show where Dana Faratian may publish in the future.

Co-authorship network of co-authors of Dana Faratian

This figure shows the co-authorship network connecting the top 25 collaborators of Dana Faratian. A scholar is included among the top collaborators of Dana Faratian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana Faratian. Dana Faratian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Rui, Dana Faratian, Andrew H. Sims, et al.. (2014). Increased STAT1 Signaling in Endocrine-Resistant Breast Cancer. PLoS ONE. 9(4). e94226–e94226. 32 indexed citations
2.
Palmieri, Carlo, et al.. (2013). Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. British Journal of Cancer. 108(10). 2039–2044. 25 indexed citations
3.
O’Mahony, Fiach C., Jyoti Nanda, Alexander Laird, et al.. (2013). The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers. Journal of Visualized Experiments. 9 indexed citations
4.
Hu, Huizhong, Alexey Goltsov, James Bown, et al.. (2012). Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer. Cellular Signalling. 25(1). 26–32. 15 indexed citations
5.
Sims, Andrew H., Annelien J.M. Zweemer, Yoko Nagumo, et al.. (2012). Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. British Journal of Cancer. 106(11). 1779–1789. 38 indexed citations
6.
Goltsov, Alexey, Dana Faratian, Simon P. Langdon, et al.. (2011). Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition. Cellular Signalling. 24(2). 493–504. 13 indexed citations
7.
Faratian, Dana, Andrew H. Sims, Peter Mullen, et al.. (2011). Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy. PLoS ONE. 6(8). e23772–e23772. 41 indexed citations
8.
Faratian, Dana, Annelien J.M. Zweemer, Yoko Nagumo, et al.. (2011). Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies. Clinical Cancer Research. 17(13). 4451–4461. 44 indexed citations
9.
Faratian, Dana, et al.. (2011). Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy. European Journal of Cancer. 47(9). 1420–1431. 15 indexed citations
10.
Macaskill, E. Jane, John M.S. Bartlett, Vicky S. Sabine, et al.. (2010). The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Research and Treatment. 128(3). 725–734. 40 indexed citations
11.
Hochgräfe, Falko, Luxi Zhang, Sandra O’Toole, et al.. (2010). Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells. Cancer Research. 70(22). 9391–9401. 141 indexed citations
12.
Katz, Elad, Andrew H. Sims, Dana Faratian, et al.. (2010). A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. British Journal of Cancer. 103(3). 401–410. 60 indexed citations
13.
Langdon, Simon P., et al.. (2010). FACTORS DETERMINING GONADOTROPHIN RELEASING HORMONE ANALOGUE SENSITIVITY. Annals of Oncology. 21. 63–63. 3 indexed citations
14.
Faratian, Dana. (2010). Systems pathology. Breast Cancer Research. 12(S4). S4–S4. 5 indexed citations
15.
Faratian, Dana, Alexey Goltsov, Anatoly Sorokin, et al.. (2009). Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab. Cancer Research. 69(16). 6713–6720. 126 indexed citations
16.
17.
Faratian, Dana, Alison F. Munro, Christopher Twelves, & John M.S. Bartlett. (2009). Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology. 54(2). 254–257. 55 indexed citations
18.
Faratian, Dana, et al.. (2009). Systems pathology—taking molecular pathology into a new dimension. Nature Reviews Clinical Oncology. 6(8). 455–464. 48 indexed citations
19.
20.
Dixon, J. Michael, Dana Faratian, Sharon White, et al.. (2007). DCIS and aromatase inhibitors. The Journal of Steroid Biochemistry and Molecular Biology. 106(1-5). 173–179. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Soonmyoung Paik Breakdown of academic impact, for papers by Kevin D. Courtney Breakdown of academic impact, for papers by Hiroyuki Takahashi Breakdown of academic impact, for papers by Li Fu Breakdown of academic impact, for papers by Philip Jonsson Breakdown of academic impact, for papers by Nancy Kerkvliet Breakdown of academic impact, for papers by Abdelbaset Buhmeida Breakdown of academic impact, for papers by Björn Erikstein Breakdown of academic impact, for papers by Naofumi Kagara Breakdown of academic impact, for papers by Rachel E. Ellsworth
Rankless by CCL
2026